Results 31 to 40 of about 46,038 (143)

Immunogenicity of the biosimilar CT-P13 infliximab or the original infliximab in Iraqi patients with Ankylosing spondylitis does not correlate with their demographic characteristics

مجلة كلية الطب, 2023
Background: Ankylosing spondylitis is a rare disease affecting people with hereditary factors. Its treatment includes life style modification and use of drugs such as the biologic agent infliximab or its biosimilar, CT-P13 infliximab.
Mohammed M. Kamil, Mohammed Abdul- Hassan Jabarah, Nizar A.l. Jasim   +2 more
doaj   +1 more source

Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial

BMJ Open
Introduction A substantial proportion of patients with inflammatory bowel disease (IBD) on intravenous infliximab require dose intensification. Accessing additional intravenous infliximab is labour-intensive and expensive, depending on insurance and ...
Jonathan P Segal, Mayur Garg, Miles P Sparrow, Gareth J Walker, Ashish Srinivasan, Peter De Cruz, Desmond Chee, Alex Boussioutas, Robert V Bryant, Georgina Hold, Gregory T Moore, Susan J Connor, Robert D Little, Mark G Ward, Jo McKenzie, Patrick Hilley, Robert B Gilmore, Manjeet Sandhu, Daniel Saitta, Elizabeth Chow, Lena Thin, Kate Lynch, Jane Andrews, Yoon K An, Emily K Wright   +24 more
doaj   +1 more source

Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure

Gut and Liver
Background/Aims: Studies on elective switching to the subcutaneous (SC) formulation of infliximab revealed comparable efficacy and safety and higher infliximab level than those exhibited by intravenous (IV) infliximab.
June Hwa Bae, Jung-Bin Park, Ji Eun Baek, Seung Wook Hong, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sung Wook Hwang   +10 more
doaj   +1 more source

Relationship Between Trough Levels of Anti-Infliximab and Serum Biomarkers in Patients With Rheumatoid Arthritis

Acta Medica Iranica
Rheumatoid arthritis is a chronic condition, characterized by the expression of antibody against self-antigens. Inflammatory cell of synovial tissues secreted numerous cytokines, include tumor necrosis factor alpha.
Sura Mohammed Lateef, Ahmed Abdul-Hassan Abbas, Mohammed Hadi Alosami   +2 more
doaj   +1 more source

The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial

Pediatric Rheumatology Online Journal, 2010
Background We evaluated the effect of infliximab on markers of inflammation in patients with juvenile idiopathic arthritis (JIA). Methods In this randomized, placebo-controlled substudy, 122 patients with JIA received infliximab 3 mg/kg + methotrexate ...
Gerloni Valeria, Fasth Anders, Baildam Eileen, Apaz Maria T, Gattorno Marco, Espada Graciela, Woo Patricia, Cuttica Ruben, Petty Ross, Martini Alberto, Lovell Daniel J, Marini Joseph C, Wagner Carrie, Visvanathan Sudha, Lahdenne Pekka, Quartier Pierre, Saurenmann Rotraud, Travers Suzanne, Mendelsohn Alan, Xu Stephen, Giannini Edward H, Ruperto Nicolino   +21 more
doaj   +1 more source

A Comparison of Intravenous Infliximab Versus Subcutaneous Infliximab on Remission Rates, Safety, Costs, Patient Preferences in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Gastro Hep Advances
Background and Aims: Infliximab, widely used as a mainstay treatment of inflammatory bowel disease (IBD), is traditionally administered intravenously. The subcutaneous (SC) formulation appears to offer a more convenient route of administration. This is a
Alejandro Nieto Dominguez, Abhishek Bhurwal, Hemant Mutneja, Sarah E. Eichinger, Bhanu Pinnam, Daniel Guifarro Rivera, Chun-Wei Pan   +6 more
doaj   +1 more source

Does Smoking Reduce Infliximab’s Effectiveness against Crohn’s Disease?

Canadian Journal of Gastroenterology, 2009
Crohn’s disease (CD) is an idiopathic inflammatory bowel disease and has no known cure. CD symptoms are treated using an array of medicines, including biological agents such as infliximab.
Neeraj Narula, Richard N Fedorak
doaj   +1 more source

Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study

Gut and Liver
Background/Aims: Infliximab treatment failure in patients with inflammatory bowel disease may result from sub-optimal infliximab trough level. An understanding of pharmacokinetics (PKs) is important to maintain an optimal trough level.
Joo Hye Song, Sung Noh Hong, Myeong Gyu Kim, Minjung Kim, Seong Kyung Kim, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim   +7 more
doaj   +1 more source

Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel

Respiratory Medicine Case Reports, 2016
Infliximab is an effective treatment for sarcoidosis patients with persistent disease despite glucocorticoids and immunosuppressive therapy. Patients receiving infliximab can experience side effects, inducing an autoimmune reaction.
Ying Zhou, Elyse E. Lower, Huiping Li, Robert P. Baughman   +3 more
doaj   +1 more source

Effect of infliximab dose increase in rheumatoid arthritis at different trough concentrations: a cohort study in clinical practice conditions

Frontiers in Medicine, 2015
BackgroundEvidence supporting treatment intensification in rheumatoid arthritis is limited and controversial. We explored outcomes of infliximab dose increases and accounted for pre-existing trough levels in patients with active rheumatoid arthritis (RA).
Chamaida ePlasencia, Teresa eJurado, Alejandro eVillalba, Diana ePeitedado, Maria Teresa López Casla, Laura eNuño, María Gema Bonilla, Ana eMartínez-Feito, Emilio eMartín-Mola, Dora ePascual-Salcedo, Alejandro eBalsa   +10 more
doaj   +1 more source